DAS181 for STOP COVID-19

Summary

It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.

Timeline

Start

2020-07-25

Primary completion

2020-09-30

Completion

2020-11-30

Outcome

Outcome not reported

Stopped: “No COVID-19 in EU countries - Sponsor withdraw in regulatory stage”

Drugs

Indications